Half life of atenolol
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Half-Life of Atenolol: A Comprehensive Overview
Introduction to Atenolol Pharmacokinetics
Atenolol is a cardioselective beta-blocker commonly used to manage hypertension and other cardiovascular conditions. Understanding its pharmacokinetics, particularly its half-life, is crucial for optimizing dosing regimens and ensuring effective therapeutic outcomes.
Elimination Half-Life in Healthy Individuals
The elimination half-life of atenolol in healthy individuals has been reported to vary between studies. Generally, the mean elimination half-life is approximately 6 to 10 hours. One study found a mean elimination half-life of 6.06 ± 2.02 hours in healthy volunteers, while another reported a half-life of about 9 hours. This variability can be attributed to differences in study design and population characteristics.
Impact of Renal Function on Atenolol Half-Life
Atenolol is primarily excreted unchanged by the kidneys, making renal function a significant determinant of its half-life. In patients with normal renal function, the half-life is around 6 to 7 hours . However, in patients with renal impairment, the half-life can be significantly prolonged. For instance, in patients with severe renal failure, the half-life can extend up to 36 hours and even reach 73.4 ± 28.8 hours in those undergoing dialysis. This necessitates dosage adjustments in patients with compromised renal function to avoid drug accumulation and potential toxicity.
Atenolol Half-Life in Special Populations
Children
In pediatric populations, the pharmacokinetics of atenolol differ slightly from adults. A study on children undergoing cardiac electrophysiologic studies reported a mean terminal elimination half-life of 4.56 ± 1.05 hours, which is shorter than that observed in adults. This suggests that children may require more frequent dosing to maintain therapeutic levels.
Dialysis Patients
For patients undergoing dialysis, the half-life of atenolol is markedly prolonged during the interdialytic period, ranging between 42 and 73 hours. However, during a standard hemodialysis session, the plasma concentration of atenolol can decrease by approximately 50%. This indicates that dialysis significantly affects atenolol clearance, and dosing schedules should be carefully managed in these patients.
Conclusion
The half-life of atenolol varies significantly based on renal function and patient demographics. In healthy individuals, it ranges from 6 to 10 hours, but it can be substantially prolonged in patients with renal impairment or those undergoing dialysis. Understanding these variations is essential for tailoring atenolol therapy to individual patient needs, ensuring both efficacy and safety.
Sources and full results
Most relevant research papers on this topic